8.52079

Fmoc-Asp-ODmab

Novabiochem^®

• Synonyme(s) : Fmoc-Asp-ODmab, N-α-Fmoc-L-aspartic acid α-4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino} benzyl ester
• Formule empirique (notation de Hill): C₃₉H₄₂N₂O₈
• Numéro CAS: 172611-77-7
• Poids moléculaire : 666.76
• Code UNSPSC : 12352209
• Nomenclature NACRES : NA.22

Propriétés

• Niveau de qualité: 200
• Gamme de produits: Novabiochem^®
• Pureté: ≥95.0% (HPLC); ≥97% (TLC)
• Forme: powder
• Capacité de réaction: reaction type: Fmoc solid-phase peptide synthesis
• Fabricant/nom de marque: Novabiochem^®
• Application(s): peptide synthesis
• Groupe fonctionnel: carboxylic acid
• Température de stockage: 15-25°C

Description

Description générale

Quasi-orthogonally-protected Asp derivative.The Dmab group can be removed selectively in the presence of tBu-based protecting groups by treatment with 2% hydrazine in DMF ^[1], making this derivative an extremely useful tool for the preparation of cyclic peptides by Fmoc SPPS or for library synthesis. Occasionally sluggish cleavage of the aminobenzyl moiety is observed ^[2,3]. In these instances, washing the support with 20% DIPEA in DMF/water (9:1) ^[2] or HCl in dioxane ^[4] has been found to be efficacious. For the on-resin synthesis of side-chain to side-chain lactam bridged peptides, the combination of Lys(ivDde) and Asp(ODmab) is particularly advantageous since both side-chains can be simultaneously unmasked in a single step.To avoid aspartimide formation, it is advisable to employ an Hmb- or Dmb-protected derivative for introduction of the preceding residue.For applications of this derivative in the synthesis of cyclic peptides, see references ^{[5 - 7]}.

Associated Protocols and Technical Articles
Cleavage and Deprotection Protocols for Fmoc SPPS

Literature references

^[1] W. C. Chan, et al. (1995) J. Chem. Soc., Chem. Commun., 2209.
^[2] S. Künzel, et al. Poster 17 presented at Solid Phase Synthesis & Combinatorial Libraries, Southampton, September 2001.
^[3] K. F. Medzihradszky, et al. (2002) Lett. Pept. Sci., 8, 1.
^[4] Albericio, et al.Poster 44 presented at American Peptide Symposium, San Diego 2005..
^[5] M. Cudic, et al. in ′Peptides 2000, Proc. 26th European Peptide Symposium′, J. Martinez & J.-A. Fehrentz (Eds), Paris, Editions EDK, 2001, pp. 203.
^[6] M. Cudic, et al. (2000) Tetrahedron Lett., 41, 4527.
^[7] J. P. Malkinson, et al. (2003) Org. Lett., 5, 5051.

Liaison

Replaces: 04-12-1176

Remarque sur l'analyse

Color (visual): white to slight yellow to beige
Appearance of substance (visual): powder
Identity (IR): passes test
Enantiomeric purity: ≥ 99.0 % (a/a)
Purity (TLC(157A)): ≥ 97 %
Purity (TLC(CMA2)): ≥ 97 %
Assay (HPLC, area%): ≥ 95.0 % (a/a)
Solubility (1 mmole in 2 ml DMF): clearly soluble
Water (K. F.): ≤ 1.0 %

To see the solvent systems used for TLC of Novabiochem^® products please click here.

Informations légales

Novabiochem is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable